Analysts' Actions: CLVS ENDP THC WRB

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Clovis Oncology ( CLVS) was upgraded at Piper Jaffray to overweight from neutral. $100 price target. Company offered positive CO-1686 data at ASCO, Piper Jaffray said.

Con-way ( CNW) was upgraded at Bank of America to buy from underperform. $46 price target. The Freight segment is improving faster than expected, BofA said.

Citrix Systems ( CTXS) was downgraded at Berenberg to sell. $49 price target. Legacy business could lag, Berenberg said.

Endo Health ( ENDP) was downgraded at Cantor Fitzgerald to sell from hold. $30 price target. Expect a prolonged restructuring period, Cantor said.

Endo Health was upgraded at Leerink Swann. $48 price target. Expectations have come down, and 2013 guidance is now achievable, Leerink Swann said.

First Horizon National ( FHN) was downgraded at Morgan Stanley to equal weight. There is limited near-term upside as the stock has outperformed its peers since the first quarter of 2012, Morgan Stanley said. http://www.thestreet.com/story/11942921/1/sodastream-could-be-a-threat-to-big-soda.html?kval=dontmiss

Haemonetics ( HAE) was initiated with a market outperform rating at JMP Securities. The company's leading market position will be bolstered by M&A, and significant margin expansion is expected ahead, JMP said. Price target is $52.

Lifepoint ( LPNT) was upgraded at Credit Suisse to outperform from neutral. Nonurban hospitals are best positioned for health care reform, Credit Suisse said.

LRR Energy ( LRE) was downgraded to sell at TheStreet Ratings.

Oracle ( ORCL) was downgraded at Berenberg to sell. $28 price target. Company may lag the pace of innovation in the software sector, Berenberg said.

Realpage ( RP) was downgraded to sell at TheStreet Ratings.

Tenet Healthcare ( THC) was upgraded at Deutsche Bank to buy. $55 price target. Stock is attractive, following the recent pullback, Deutsche Bank said.

VMWare ( VMW) was downgraded at Berenberg to sell. $57 price target. Company may be left behind by new technology trends, Berenberg said.

WR Berkley ( WRB) was upgraded at Bank of America/Merrill Lynch to buy from neutral. $46 price target. Stock is attractive, following a 12% pullback, BofA/Merrill said.

Stock Comments / EPS Changes

Brown-Forman ( BF.B) estimates were reduced at UBS. Lower volume and pricing increased, said UBS.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

Clovis Sell-Off May Be Overdone

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why